Upadacitinib
Upadacitinib
Upadacitinib (pronounced as "you-pa-da-si-ti-nib") is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is classified under the group of drugs known as Janus kinase inhibitors.
Etymology
The name "Upadacitinib" is derived from the drug's mechanism of action. "Upada" is a prefix used in pharmacology to denote drugs that inhibit the action of Janus kinase, and "citinib" is a suffix used for drugs that inhibit tyrosine kinases.
Usage
Upadacitinib is used to treat moderate to severe rheumatoid arthritis in adults who have not responded well to methotrexate. It is also used to treat psoriatic arthritis and ankylosing spondylitis.
Mechanism of Action
Upadacitinib works by inhibiting the action of Janus kinase, a type of enzyme that plays a crucial role in the inflammatory process. By blocking this enzyme, Upadacitinib helps to reduce inflammation and relieve the symptoms of arthritis.
Side Effects
Common side effects of Upadacitinib include upper respiratory tract infections, nausea, cough, and fever. Serious side effects may include blood clots, infections, and liver problems.
Related Terms
- Janus kinase inhibitors
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Methotrexate
External links
- Medical encyclopedia article on Upadacitinib
- Wikipedia's article - Upadacitinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski